What Is TRT? What Does TRT Stand For: 5 Essential Facts
WHAT IS TRT? WHAT DOES TRT STAND FOR: 5 ESSENTIAL FACTS
TRT stands for testosterone replacement therapy. It is prescribed testosterone for men whose own production has failed and who have the symptoms to match. The TRT meaning sits in the word replacement: it puts back a missing hormone. It does not add extra to a normal level.
So what is TRT in practice? This guide covers the forms, who qualifies, what the big trials found, the risks, and the blood tests that make it a therapy. Every figure comes from a PubMed abstract, the drug label or an FDA notice listed at the end. The full series is on the TRT and hormones hub.
What is TRT in three numbers
Three numbers frame the answer to what is TRT. How safe it was for the heart in the largest trial, what a normal testosterone level is, and how many men really qualify.
Heart attack, stroke or heart death: TRT vs placebo
In TRAVERSE, 182 men on testosterone and 190 on placebo had a major heart event. The hazard ratio was 0.96 (PMID 37326322).
Bottom of the normal range in healthy young men
Across 9,054 men, the healthy range was 264 to 916 ng/dL, with a median of 531 (PMID 28324103).
Men with low testosterone and the symptoms
About 24 percent of 1,475 men had testosterone under 300 ng/dL. Only 5.6 percent also had the symptoms (PMID 17698901).
Every figure here comes from a PubMed abstract, the Depo-Testosterone prescribing information or an FDA notice, listed at the end. Doses appear only as the label or a trial states them. This page is education, not medical advice.
What this what is TRT guide covers
What is TRT: the definition, the forms, the label, and why every form shuts down natural production.
Who qualifies: the Endocrine Society criteria and a 2026 JAMA review, the normal range, and what rules TRT therapy out.
The evidence: the Testosterone Trials, TRAVERSE and the 2025 FDA label change.
Benefits, risks and monitoring, plus fertility and how TRT therapy differs from a steroid cycle.
Not covered
A dose for you. A prescriber sets the dose against your blood levels.
Women and teenagers. That is a separate clinical topic.
Each side effect in depth. Those have their own pages.
See high hematocrit on TRT, blood pressure on TRT, water retention, estradiol on TRT, low libido on TRT, TRT and sleep and TRT and fertility.
What is TRT? Definition, forms, and what the label says
To see the TRT meaning, start with the body. Testosterone is made in the testes. The brain controls it: the hypothalamus signals the pituitary, and the pituitary releases LH, which tells the testes to work.
If the testes fail, that is primary hypogonadism. If the brain signal fails, that is secondary hypogonadism. Either way testosterone falls and symptoms follow.
So what is TRT? It supplies testosterone from outside, so blood levels return to the range of a healthy young man. The Endocrine Society recommends it for men with symptomatic deficiency, after a talk about benefits, risks and monitoring (PMID 29562364).
The Depo-Testosterone label gives two approved conditions: primary hypogonadism and hypogonadotropic hypogonadism. It adds that safety and efficacy in age-related hypogonadism have not been established (Depo-Testosterone label).
That last line matters. Many men asking what TRT therapy is are in their forties or fifties, with levels that drifted down with age and weight. The label does not cover that group.
| Form | How it is given and what levels do | Read as |
|---|---|---|
| Cypionate or enanthate injection | Into the muscle. Label range for replacement: 50 to 400 mg every 2 to 4 weeks (Depo-Testosterone label). Levels peak, then fall before the next dose. See TRT injection frequency. | Most prescribed |
| Skin gel | Daily. In TRAVERSE the 1.62 percent gel was adjusted to keep levels at 350 to 750 ng/dL (PMID 37326322). Can transfer to partners and children. | Used in the big trials |
| Pellets | Implanted under the skin and lasts months. Rule of thumb: high early levels that fade. No dose change once placed. | Convenient, inflexible |
| Oral undecanoate | Capsules with meals. Absorption depends on dietary fat. | Newer option |
| Nasal gel | Two or three times a day. Short acting. | Niche |
| hCG, clomiphene, enclomiphene | Push your own production instead of replacing it. Not TRT therapy by definition. See TRT and fertility. | Alternatives |
Every form shares one effect. The brain reads outside testosterone as its own, so LH falls. The testes then slow both testosterone and sperm production.
That is why TRT therapy suppresses fertility in every form, and why the label lists low sperm count as a precaution (Depo-Testosterone label). The two common esters are covered in testosterone cypionate and testosterone propionate.
Who qualifies for TRT therapy: the criteria in numbers
What is TRT for, and who gets it? Both American guidelines ask for two things. First, symptoms that fit testosterone deficiency. Second, low testosterone on at least two separate morning samples with a reliable test (PMID 29562364, PMID 42207626).
| Criterion | What the source states | Read as |
|---|---|---|
| Symptoms and low levels | Diagnose only with symptoms and clearly, repeatedly low testosterone (PMID 29562364). | Both halves required |
| Which symptoms count | In 3,369 European men, only weak morning erections, low desire and erectile dysfunction tracked low testosterone. Fatigue and low mood were not specific (PMID 20554979). | Sexual symptoms carry the weight |
| Two morning tests | Fasting morning total testosterone, then a repeat to confirm (PMID 29562364). The label asks for two separate days (Depo-Testosterone label). | One afternoon test is not a diagnosis |
| The threshold | Healthy range in non obese men 19 to 39: 264 to 916 ng/dL (PMID 28324103). A 2026 JAMA review uses 264 to 300 ng/dL (PMID 42207626). | About 264 to 300 ng/dL |
| Free testosterone | Check it when total is borderline or SHBG is off (PMID 29562364). | Total can mislead |
| Find the cause | Look for the reason: LH level, obesity, opioids, sleep apnea, past steroid use, pituitary disease (PMID 29562364). | Before the prescription |
| Do not start | Near term fertility plans, breast or prostate cancer, a prostate lump or raised PSA (PMID 29562364). | Hard stops |
| Age-related decline | Not established on the label, and the FDA kept that limit in 2025 (Depo-Testosterone label) (FDA, February 2025). | The grey zone |
This explains why so many men told they have low T do not meet the definition. A quarter of men were under 300 ng/dL, but only 5.6 percent had the full syndrome (PMID 17698901).
Fatigue, low mood and belly fat are common at every testosterone level. The specific signs are sexual (PMID 20554979). Our low testosterone symptoms guide ranks them, and total vs free testosterone explains when the free number matters.
The TRT therapy trials: from the 2010 scare to TRAVERSE and the 2025 label
For years, the honest answer to what is TRT doing to the heart was: nobody knew. The way that question got answered is the clearest way to understand the therapy.
2010. A trial gave testosterone gel to 209 frail men over 65 with high rates of hypertension, diabetes and obesity. It was stopped early: 23 men on testosterone had heart related events, against 5 on placebo (PMID 20592293).
The authors warned that the small size and unusual group limited what could be concluded (PMID 20592293).
2013 and 2014. Two observational studies raised the alarm. In 8,709 veterans, death, heart attack or stroke at three years was 25.7 percent on testosterone, against 19.9 percent without (PMID 24193080).
In 55,593 men, non fatal heart attacks in the 90 days after a first prescription ran 1.36 times the prior rate (PMID 24489673). Neither study was randomised. Still, they led to a boxed heart warning on the label from 2015.
The randomised trials. In TEAAM, 308 men over 60 took gel or placebo for three years. Artery wall thickness and coronary calcium did not differ between groups (PMID 26262795).
The Testosterone Trials gave 790 men over 65 gel or placebo for a year. Sexual function improved and mood a little. Vitality and walking did not (PMID 26886521).
A substudy of those men did find more soft plaque growth, 41 cubic millimetres more, in men who already had severe artery disease (PMID 28241355).
TRAVERSE. This trial settled the heart question. It enrolled 5,246 men aged 45 to 80 with symptoms, two low fasting levels and high heart risk (PMID 37326322).
They got 1.62 percent gel adjusted to 350 to 750 ng/dL, or placebo. Major heart events did not rise. Atrial fibrillation, acute kidney injury and blood clots in the lung did (PMID 37326322).
A 2024 analysis pooled 106 placebo controlled trials. It found no difference in major heart events. The extra arrhythmia showed up only in TRAVERSE itself (PMID 38553429).
2025. On 28 February 2025 the FDA changed labels on all testosterone products. It removed the heart risk wording from the boxed warning and added a blood pressure warning (FDA, February 2025).
It also kept the limit on use for age-related decline (FDA, February 2025). The label now says to check blood pressure regularly, and not to use it with uncontrolled hypertension (Depo-Testosterone label). More in blood pressure on TRT.
What TRT therapy does: benefits measured in randomised trials
What is TRT able to deliver once levels are back to normal? Less than the marketing says, and more than nothing.
The pattern is consistent. Sexual desire and activity improve. Anemia and bone density improve. Mood improves a little. Energy, memory and erections barely move.
| Outcome | What was measured | Read as |
|---|---|---|
| Sexual desire and activity | In 1,161 TRAVERSE men with low libido, sexual activity and desire improved by 6 months and held to 24 months (PMID 37589949). In the Testosterone Trials, 10 of 12 measures improved (PMID 27355400). | Most reliable benefit |
| Erections | Improved in the Testosterone Trials (PMID 26886521). Not better than placebo over two years in TRAVERSE (PMID 37589949). | Mixed |
| Mood | Small but significant gains in mood and energy, not in memory or sleep (PMID 38205962). | Small, real |
| Vitality | No significant gain on the fatigue scale (PMID 26886521). | Weak |
| Anemia | In 62 anemic older men, 58.3 percent on testosterone were no longer anemic at 12 months, against 22.2 percent on placebo (PMID 28241237). | Consistent |
| Bone density | Spine bone density rose 7.5 percent against 0.8 percent on placebo in a year (PMID 28241231). | Density improves |
| Fractures | 3.50 percent on testosterone against 2.46 percent on placebo over 3.2 years (PMID 38231621). | Denser bone, more fractures |
| Memory | No change in memory tests over a year in 493 men (PMID 28241356). | No benefit |
| Diabetes | No difference in TRAVERSE (PMID 38315466). In T4DM, new diabetes fell from 21 to 12 percent in obese men on a lifestyle program (PMID 33338415). | Depends on the group |
Muscle is the question most readers here care about. In 61 healthy young men with their own production switched off, gains rose in step with the dose (PMID 11701431).
The dose that held testosterone at 542 ng/dL, mid normal, added 3.4 kg of lean mass in 20 weeks. Mood, sexual function and PSA did not change at any dose (PMID 11701431).
A man restored to the middle of the range gets the bottom of that curve. Higher levels bring more muscle, plus the hematocrit and cholesterol changes that come with them.
TRT therapy risks and side effects by the evidence
What is TRT going to cost you in side effects? The risks of TRT are better measured than most things on this site. It has a label, two large trial programs and a 106 trial analysis behind it.
| Risk | Strongest evidence | Read as |
|---|---|---|
| Heart attack, stroke | No excess in TRAVERSE (PMID 37326322) or across 106 trials (PMID 38553429). Boxed heart wording removed (FDA, February 2025). | Settled for men like those enrolled |
| Atrial fibrillation, lung clots, kidney injury | More frequent on testosterone in TRAVERSE (PMID 37326322). Not confirmed when other trials were pooled (PMID 38553429). | Real in one large trial |
| Blood pressure | Testosterone products raise blood pressure. New label warning (FDA, February 2025). See blood pressure on TRT. | Label warning |
| Thick blood | The most common side effect, highest with short acting injections (PMID 28526632). See high hematocrit on TRT. | Monitored |
| Fractures | 3.50 against 2.46 percent despite denser bone (PMID 38231621). | Unexpected excess |
| Prostate | In screened men, prostate cancer and urinary problems did not differ from placebo. PSA rose more in year one (PMID 38753865). | Low with screening |
| Fertility | Sperm production falls on every form (Depo-Testosterone label). It returned in a median 3.4 months after stopping (PMID 16650651). | Reversible after |
| Sleep apnea | Untreated severe sleep apnea is a reason not to start (PMID 29562364). See TRT and sleep. | Screen first |
| Estradiol, water, libido | Dose and ester dependent. See estradiol on TRT, water retention, low libido on TRT. | Symptom driven |
The short version of what is TRT risk: the heart question is answered for men like those in TRAVERSE. Blood pressure, hematocrit, fertility and the fracture signal are the measured costs.
Every one of them is either monitored or on the label. No trial measured a man on two or three times the label range without bloodwork.
What TRT therapy requires: the monitoring that makes it a therapy
What is TRT without monitoring? A steroid cycle with a prescription. The trials were safe because they measured.
The Endocrine Society asks doctors to check symptoms, side effects, testosterone, hematocrit and the prostate on a fixed schedule (PMID 29562364). The label adds hematocrit and blood pressure (Depo-Testosterone label).
| Check | Why | Read as |
|---|---|---|
| Total testosterone | Confirms the target. TRAVERSE aimed for 350 to 750 ng/dL (PMID 37326322). See TRT bloodwork. | Scheduled |
| Hematocrit | The most common side effect (PMID 28526632). On the label (Depo-Testosterone label). | Can change the dose |
| Blood pressure | Check regularly, especially with hypertension (Depo-Testosterone label). | Label warning |
| PSA and prostate | A baseline risk check and a set plan catch serious cancer and avoid needless biopsies (PMID 38753865). | Men over 40 |
| Lipids | Cholesterol may rise on androgens (Depo-Testosterone label). HDL fell with dose in healthy men (PMID 11701431). | Scheduled |
| Estradiol | Not routine. Check if breast tenderness, water retention or mood swings appear. See estradiol on TRT. | If symptoms |
| Semen analysis | Before starting, if fertility matters. Production recovers over months after stopping (PMID 16650651). | Before the first dose |
Two tools help with the numbers: the free testosterone calculator and the TRT dosage calculator, which converts a prescribed dose to millilitres. Neither chooses a dose.
TRT vs a steroid cycle: where the trials draw the line
What is TRT, and what is a cycle? Online, the word TRT is used loosely, far from the TRT meaning on the label. On forums, men call self sourced testosterone TRT simply because the dose is lower than a typical cycle. Bloodwork in those reports ranges from regular to none.
That is a description of a pattern, not evidence or advice. The measured data tell a clearer story.
The label range for replacement is 50 to 400 mg every 2 to 4 weeks (Depo-Testosterone label). In the dose study, 125 mg a week held testosterone at 542 ng/dL, inside the normal range (PMID 11701431).
Higher weekly doses pushed levels to 1,345 and 2,370 ng/dL. Lean mass, hemoglobin and IGF-1 rose, and HDL fell, along the same line (PMID 11701431).
Every safety result on this page came from men adjusted to 350 to 750 ng/dL (PMID 37326322). None of it applies at 1,345.
So the difference between TRT and a cycle is not the molecule. It is the blood level, and whether anyone is measuring it. Whether that makes TRT a steroid is answered in is TRT a steroid, and recovery after a cycle in post cycle therapy.
Five mistakes men make about what TRT is
Each mistake about what is TRT comes from reading a number without its definition, or a trial without its population.
1. Diagnosing from one afternoon test. The label and guidelines need two morning tests on separate days (Depo-Testosterone label) (PMID 29562364). Levels drop through the day and with illness, poor sleep and stress.
2. Diagnosing from fatigue. Only the three sexual symptoms tracked low testosterone in 3,369 men (PMID 20554979). A quarter of men are under 300 ng/dL, but only 5.6 percent have the syndrome (PMID 17698901).
3. Chasing a high number. Mood, sexual function and PSA did not improve with higher doses, while hematocrit and HDL got worse (PMID 11701431).
4. Reading TRAVERSE as a blanket all clear. It enrolled screened men with two low levels, kept in range (PMID 37326322). It says nothing about a man with normal testosterone on twice the label range.
5. Starting without a fertility plan. Sperm took a median 3.4 months to recover after stopping, and 10 percent were not back at a year (PMID 16650651). Ask about hCG, clomiphene or sperm banking first.
Verdict: 5 essential facts about what TRT is
1. TRT stands for testosterone replacement therapy. That is the TRT meaning. It replaces a missing hormone in men with symptoms and confirmed low levels (PMID 29562364).
2. The diagnosis needs two morning tests and real symptoms. Only 5.6 percent of men meet the full definition (PMID 17698901).
3. It did not raise heart attacks or strokes in TRAVERSE. The rates were 7.0 and 7.3 percent (PMID 37326322).
4. It reliably helps libido, anemia and bone density. It does little for energy or memory (PMID 37589949, PMID 37889486, PMID 26886521).
5. It has measured costs. Higher blood pressure, thicker blood, paused fertility and more fractures (FDA, February 2025) (PMID 28526632, PMID 38231621).
So what is TRT? A defined therapy for a defined deficiency, kept in the normal range and checked with bloodwork. The forum version without a trough level is a different thing wearing the same name.
What is TRT: frequently asked questions
What does TRT stand for?
TRT stands for testosterone replacement therapy. That is the TRT meaning in full. It is prescribed testosterone that restores normal levels in men whose own production is deficient and who have symptoms. The label lists it as replacement therapy for deficiency (Depo-Testosterone label).
What is TRT and how does it work?
What is TRT doing in the body? It supplies testosterone from outside when the testes or the brain signal fail. It acts on the same receptors as natural testosterone. In the big trials the dose kept levels at 350 to 750 ng/dL (PMID 37326322). Your own testosterone and sperm production pause while on it.
Who qualifies for TRT?
A man with symptoms and low testosterone on two fasting morning tests. The cause should be checked, with no contraindication such as prostate cancer or near term fertility plans (PMID 29562364). The cut off is about 264 to 300 ng/dL (PMID 28324103, PMID 42207626).
Is TRT therapy safe?
For men who qualify and are monitored, TRAVERSE found no rise in heart attack or stroke (PMID 37326322). It did find more atrial fibrillation and lung clots, and more fractures (PMID 38231621). The FDA added a blood pressure warning in 2025 (FDA, February 2025).
What is the TRT dosage?
The Depo-Testosterone label states 50 to 400 mg every 2 to 4 weeks, adjusted to response (Depo-Testosterone label). The trials adjusted gel to blood levels of 350 to 750 ng/dL (PMID 37326322). A prescriber sets the dose against blood tests.
How long does TRT therapy take to work?
Sexual desire and activity improved by 6 months and held to 24 months (PMID 37589949). Anemia corrected in 41 percent by 6 months and 45 percent by 12 (PMID 37889486).
What testosterone level does TRT aim for?
The normal range. In the TRAVERSE safety trial, the gel dose was adjusted to keep men between 350 and 750 ng/dL (PMID 37326322). Higher doses produced 1,345 and 2,370 ng/dL in one study, which is no longer replacement (PMID 11701431).
Does TRT therapy affect fertility?
Yes, in every form. It suppresses sperm production (Depo-Testosterone label). After stopping, sperm recovered in a median 3.4 months, 90 percent of men by 12 months (PMID 16650651).
Sources and further reading
Every figure on this page comes from one of the 29 sources below. That is 27 papers checked against PubMed, the Depo-Testosterone label on DailyMed, and the FDA notice of February 2025. Forum descriptions carry no reference number. Reference links are dofollow to support open science.
Verified
Verified
Verified
Verified
Verified
Verified
Verified
Verified
Verified
Verified
Verified
Verified
Verified
Verified
Verified
Verified
Verified
Verified
Verified
Verified
Verified
Verified
Verified
Verified
Verified
Verified
Verified
Verified
Verified
Keep reading the TRT series
Four pages from the series: the labs, the symptoms that count, fertility, and the line between therapy and a cycle.
Final Educational Note
This article is educational and is not medical advice. It reports what guidelines, trials, the drug label and the FDA say about testosterone replacement therapy. TRT therapy needs a diagnosis, a prescriber and ongoing monitoring.
Doses appear only as the label or a trial states them. This page gives no schedule or protocol and does not encourage performance enhancing drug use, which carries serious health and legal risks. More guides sit on the TRT and hormones hub and the PED side effects hub.
Chest pain, sudden breathlessness, one sided leg swelling, a sudden severe headache or weakness, or palpitations on testosterone need a doctor at once. Reference ranges vary by lab. Read more on the about page and in the full disclaimer.
